Arijit Bhowmick, Ph.D. Email & Phone Number

South San Francisco, California, Us

Drug discovery and development from early stage screening to DC nomination

Scientific advisor in oligonucleotide therapeutics space helping clients take strategic/investment decisions

Tarrytown, New York, Us

Headed the NAT group at Regeneron (comprising 14 FTE reports, 3 teams) working on several internal and collaboration projects related to siRNA/ASO/mRNA/CRISPR, across several disease areas and targets.

Tarrytown, New York, Us

- Built a therapeutic mRNA discovery and development team ground-up, to add to Regeneron's expanding efforts in the area of nucleic acid therapeutics - Established mRNA design and generation (small and mid scale) pipeline for therapeutics/tool development- Led 3 teams focused on RNA/Oligonucleotide based therapeutics and expanded technology/platform development efforts by initiating collaborations with multiple groups within the company

Tarrytown, New York, Us

- Built the ex-vivo gene editing team under VI-Next umbrella to add to Regeneron's expanding genetic medicine efforts. Established gRNA design and screening (on/off target effect analysis) pipeline to support in-vivo/ex-vivo gene editing efforts- Expanded both the oligo therapy and editing teams to support oligo therapy and gene editing needs across multiple indications and disease areas- Worked with BD to evaluate external assets in the RNA therapy space for partnerships and/or acquisitions

Tarrytown, New York, Us

- Built the oligo therapy core team at Regeneron under the VI-Next umbrella (lab set up, FTE hiring, strategy/planning), with primary focus on R&D efforts related to nucleic acid based drug discovery and technology development (RNAi, ASO, Aptamers)- Established Regeneron's oligonucleotide designing (siRNA, ASO, SSO), screening and discovery pipeline- Initiated technology/platform development efforts related to nucleic acid therapeutics targeted delivery and chemistry- Worked with internal collaborators and external partners to drive RNA based drug discovery and development at Regeneron- Worked with Regeneron's scientific leadership team and BD to develop strategies for expansion of efforts in genetic medicine space

Larkspur, California, Us

• Led a team of biologists and chemists to establish Vitrisa’s drug discovery pipeline• Created lead molecule profile (LMP) for drug candidates based on target occupancy and half-life modeling, indication, MOA prediction, and analysis of competitive molecules/assets, safety profile• Designed strategies for screening and discovery of RNA ligands, from early-stage discovery to IND candidate nomination• Used chemical modifications and devised SAR strategies to improve potency and stability of RNA aptamers for ophthalmology indications• Worked with CROs to plan in-vivo tox, pk/pd studies to support IND enabling efforts • Designed IP strategies and wrote white papers, tech summaries and patent applications surrounding new drug candidates, platform technologies, and processes• Worked with the C-suite to develop pitch and due-diligence decks for financing and BD partnerships• Managed drug discovery efforts across multiple targets and indications while working with cross functional teams and CROs

New York, Ny, Us

Technology developed in post-doctoral work selected among the top in 20 NY/NJ by the ELabNYC accelerator program 2016-2017• Developed scientific, business, and IP strategies to launch a biotech startup based on the novel drug discovery platform technology developed in our lab (http://www.elabnyc.com/directory/arijit-bhowmick/) • Analyzed competing/related technologies and interacted with experts in the field to develop ideas for improving our platform • Identified niche areas for application based on SWOT analysis of our technology and unmet needs• Communicated our science to investors, lawyers, HCPs and industry professionals and built relationships for RnD and financing(Elab is a prestigious competitive Bio and Health Tech accelerator program in NYC run by Design Technologies and supported by Eli Lilly, Pfizer, Roche, Kaneka and Alexandria Launch labs. Every year Elab selects 20 promising innovations in biotech/health- tech to accelerate the development of technologies into successful businesses)--

Bronx, New York, Us

Lab of Matthew Levy • Developed a novel aptamer SELEX platform to discover fully chemically modified aptamers (Selected among the top 20 technologies from NY/NJ by the ELabNYC accelerator program 2016-2017)• Applied the platform to identify chemically modified aptamers to GPR75, PDL1 and fD (licensed from Einstein by a privately funded biotech)• Developed aptamer- siRNA/small molecule conjugates for targeted delivery• Worked on aptamer functionalized LNPs for delivery of mRNA and siRNA cargo• Spearheaded drug discovery efforts in an industry-academia collaboration from early discovery and screening for leads, lead optimization, characterization, and delivery to industry team• Key techniques : oligo solid phase synthesis and purification, siRNA and aptamer design, RNA folding and RNA-protein interaction, mRNA design and generation, SELEX, NGS, cell culture models for drug screening (2D/3D and primary cultures), binding assays (Octet, Biacore), Flowcytometry, cloning etc.

Bronx, New York, Us

Licensing and commercialization of technologies developed at Einstein and Montefiore Medical Center (MMC)• Analyzed Invention Disclosures for patent-ability/marketability and performed scientific due diligence and competitive landscape analysis of technologies developed at Einstein and MMC.• Evaluated potential market opportunities for each technology. • Created tech summaries for each portfolio by translating complex scientific/clinical data into simple brief summary/presentation formats aimed at diverse audiences such as HCPs, investors, KOLs and industry leaders.• Executed marketing campaign for each portfolio by reaching out to and interacting with leading industry professionals.• Identified and contacted potential commercialization/licensing partners and participated in negotiation discussions resulting from marketing efforts.• Served as the primary liaison between Einstein researchers and interested external partners for the selected technologies.

Education record

Doctor Of Philosophy (Phd), Structural Immunology

Master Of Science (Ms), Biochemistry

Bachelor Of Science (B.Sc.), Chemistry And Biotechnology

High School